Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Leibowitz-Amit, Raya; Templeton, Arnoud J.; Omlin, Aurelius; Pezaro, Carmel; Atenafu, Eshetu G.; Keizman, Daniel; Vera‐Badillo, Francisco; Seah, Jo-An; Attard, Gerhardt; Knox, Jennifer J.; Sridhar, Srikala S.; Tannock, Ian F.; Bono, Johann S. de; Joshua, Anthony M.

doi:10.1093/annonc/mdt581

Cited by 97 publications

(74 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…51 A number of factors potentially predicting the treatment outcome, such as serum lactate dehydrogenase 32,52 and alkaline phosphatase, 53 have been recognized as potential markers for the treatment of APC. In addition, a number of studies including post-hoc analysis have further provided new insights for a higher NLR predicting lower response rate to abiraterone, 54 and a higher dNLR (dNLR = absolute neutrophil count / white blood cells -absolute neutrophil count) predicting shorter OS to docetaxel 55 (post-hoc analysis from VENICE and TAX327 studies), whereas cabazitaxel had a comparable effect on OS in patients with a higher NLR in a post-hoc analysis from TROPIC study. 56 Taken together, these findings provide some information for clinicians in the decision-making of treatment for APC.…”

Section: Prognostic Factors To Assist Decision-makingmentioning

confidence: 99%

Current treatment strategies for advanced prostate cancer

et al. 2017

View full text Add to dashboard Cite

During the past decade, treatment strategies for patients with advanced prostate cancer involving stage IV (T4N0M0, N1M0 or M1) hormone-sensitive prostate cancer and recurrent prostate cancer after treatment with curative intent, as well as castration-resistant prostate cancer, have extensively evolved with the introduction and approval of several new agents including sipuleucel-T, radium-223, abiraterone, enzalutamide and cabazitaxel, all of which have shown significant improvement on overall survival. The appropriate use of these agents and the proper sequencing of these agents are still not optimized. The results of several recently reported randomized controlled trials and retrospective studies could assist in developing a treatment strategy for advanced prostate cancer. In addition, prospective studies and molecular characterization of tumors to address these issues are ongoing.

show abstract

Section: Prognostic Factors To Assist Decision-makingmentioning

confidence: 99%

Current treatment strategies for advanced prostate cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Several studies reported positive correlations between high NLR and worse prognosis in several types of malignancies from various organs such as the lung, colon, pancreas, and stomach [4][5][6][7]. In PCa, NLR was reportedly correlated with worse prognosis in metastatic castration-resistant prostate cancer (CRPC) [8,9]. One recent retrospective study reported that a higher NLR is a highly sensitive and specific predictor of a recurrent…”

Section: Introductionmentioning

confidence: 99%

High preoperative neutrophil–lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…An NLR of less than five has been shown to be predictive of PSA response to abiraterone. 34 In a subgroup analysis of the TROPIC trial, Lorente et al demonstrated that lower NLR (≤3.0) was associated with an improved response to cabazitaxel. 35 These results were not replicated in the C-EAP population.…”

Section: Predictive Factorsmentioning

confidence: 99%

Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel

Yokom

Stewart

Alimohamed³

et al. 2018

CUAJ

View full text Add to dashboard Cite

Introduction: Cabazitaxel is one of several treatment options available for patients with metastatic castration-resistant prostate cancer who have progressed on docetaxel. Little is known about clinical factors that influence prognosis or treatment response for patients receiving cabazitaxel. Identifying prognostic and predictive factors could contribute to the optimal selection of patients for treatment after docetaxel. Methods: A retrospective review of patients enrolled on the cabazitaxel Canadian Early Access Program (C-EAP) was performed. Clinical factors were analyzed by univariable and multivariable Cox proportional hazards and logistic regression analysis to identify independent predictors of prognosis and response. Results: Forty-five patients from five centres in Canada were included in this study. On multivariable analysis, lower hemoglobin was associated with shorter survival. No other factors were independently associated with survival, prostate-specific antigen (PSA) response or primary PSA progression. Conclusions: Clinical factors predicting survival or treatment response were not identified for men with castration-resistant prostate cancer receiving cabazitaxel. Larger studies may be necessary to identify clinical factors and biomarkers that identify whether patients should or should not receive cabazitaxel.

show abstract

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Cited by 97 publications

References 20 publications

Current treatment strategies for advanced prostate cancer

Current treatment strategies for advanced prostate cancer

High preoperative neutrophil–lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy

Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel

Contact Info

Product

Resources

About